Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients

Journal of Clinical Oncology

Volumn 21, Issue 2, 2003, Pages 306-312

  Gradilone, Angela ^a   Gazzaniga, Paola ^a   Ribuffo, Diego ^a   Scarpa, Susanna ^a   Cigna, Emanuele ^a   Vasaturo, Fortunata ^a   Bottoni, Ugo ^a   Innocenzi, Daniele ^a   Calvieri, Stefano ^a   Scuderi, Nicoló ^a   Frati, Luigi ^a   Aglianò, Anna Maria ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; SURVIVIN; BAX PROTEIN, HUMAN; BCL2L1 PROTEIN, HUMAN; BIRC5 PROTEIN, HUMAN; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN; ONCOPROTEIN; PRIMER DNA; PROTEIN P53; RNA; TUMOR ANTIGEN; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLOW UP; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SENTINEL LYMPH NODE; SOUTHERN BLOTTING; ADULT; AGED; CHEMISTRY; ENZYME IMMUNOASSAY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LYMPH NODE; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODES; MALE; MELANOMA; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037440238     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.08.066     Document Type: Article

References (31)

1. Balch CM, Soong S-J, Gershenwld JE, et al: Prognostic factors analysis of 17600 melanoma patients: Validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 19:3622-3634, 2001
2. Morton DL, Thompson JF, Essner R, et al: Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: A multicenter trial. Ann Surg 230:453-465, 1999
3. Arends MJ, Willie AM: Apoptosis: Mechanisms and roles in pathology. Int Rev Exp Pathol 32:223-254, 1991
4. Tompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 267:1456-1462, 1995
5. Tsujimoto Y, Cossmann J, Jaffe E, et al: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440-1443, 1985
6. McDonnell TJ, Troncoso P, Brisbay SM, et al: Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944, 1992
7. Hague A, Moorghen M, Hicks D, et al: bcl-2 expression in human colorectal adenomas and carcinomas. Oncogene 9:3367-3370, 1994
8. Ben-Ezra JM, Kornstein MJ, Grimess MM, et al: Small-cell carcinoma of the lung express the Bcl-2 protein. Am J Pathol 145:1036-1040, 1994
9. Joensuu H, Pylkkanen L, Tokkanan S: Bcl-2 protein expression and long-term survival in breast cancer. Am J Path 145:1191-1198, 1994
10. Lu QL, Elia G, Lucas S, et al: bcl-2 proto-oncogene expression in Èpstein-Barr-associated nasopharyngeal carcinoma. Int J Cancer 53:29-35, 1993
11. Tang L, Tron VA, Reed JC, et al: Expression of apoptosis regulators in cutaneous malignant melanoma. Clin Cancer Res 4:1865-1871, 1998
12. Selzer E, Schagbauer-Wadl H, Okamoto I, et al: Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines. Melanoma Res 8:197-203, 1998
13. Morales-Ducret C, van de Rjjn M, LeBrun DP, et al: bcl-2 expression in primary malignancies of the skin. Arch Dermatol 131:909-912, 1995
14. Oltvai Z, Milliman C, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog Bax, that accelerates programmed cell death. Cell 774:609-619, 1993
15. Boise LH, Gonzalez Garzia M, Postema CE, et al: bcl-x, a bcl-2 related gene that function as a dominant regulator of apoptotic cell death. Cell 74:597-608, 1987
16. Leiter J, Schmid RM, Kaskel P, et al: Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch Dermatol Res 292:225-232, 2000
17. LaCasse EC, Baird S, Korneluk RG, et al: The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17:3247-3259, 1998
18. Grossman D, McNiff JM, Li F, et al: Expression and targeting of the apoptosis inhibitor survivin in human melanoma. J Invest Dermatol 113:1076-1081, 1999
19. Chiodino C, Cesinaro AM, Ottani D, et al: Expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin. J Invest Dermatol 113:415-418, 1999
20. Sela B: Survivin: Anti-apoptosis protein and a prognostic marker for tumor progression and recurrence. Harefuah 141:103-107, 2002
21. Bostick PJ, Morton DL, Turner RR, et al: Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 17:3238-3244, 1999
22. Hochberg M, Lotem M, Shiloni E, et al: Expression of tyrosinase, MIA and Mart-1 in sentinel lymph nodes of patients with malignant melanoma. Br J Dermatol 146:244-249, 2002
23. Balch CM, Buzaid AC, Soong S-J, et al: Final version of the American Joint Committee on Cancer Staging System for cutaneous melanoma. J Clin Oncol 19:3635-3648, 2001
24. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid-guanidinium-thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159, 1987
25. Kawasaki H, Altieri CD, Lu CD, et al: Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58:5071-5074, 1998
26. Lu CD, Altieri DC, Tanagawa N: Expression of a novel apoptosis gene, survivin, correlates with tumor cell apoptosis and p53 accumulation in gastric carcinoma. Cancer Res 1:1808-1812, 1998
27. Swana HS, Grossman D, Anthony JN, et al: Tumor content of the antiapoptotic molecule survivin and recurrence of bladder cancer. JAMA 341:452-453, 1999
28. Gradilone A, Greco C, Gazzaniga P, et al: BAX gene expression in melanoma metastases. J Invest Dermatol 106:382, 1996 (letter)
29. Gazzaniga P, Gradilone A, Vercillo R, et al: bcl-2/bax mRNA expression ratio as prognostic factor in low grade urinary bladder cancer. Int J Cancer 69:100-104, 1996
30. Gautshi O, Tschopp S, Olie RA, et al: Activity of a novel bcl-2/bcl-xL bispecific antisense oligonucleotide against tumors of diverse histologic origin. J Natl Cancer Inst 93:463-471, 2001
31. Fulda S, Friesen C, Los M, et al: Betulinic acid triggers CD95 (APO-1/Fas)-and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 57:4956-4964, 1997